靶点介导的药物处置模型在单克隆抗体药物研发中应用的探讨

doi:10.12092/j.issn.1009-2501.2018.03.001

摘要/Abstract

摘要：

近年来，国内外诸多企业正在积极地进行单克隆抗体药物的研发和申报。作为一种大分子蛋白药物，单克隆抗体因其特殊的结构和生理性质，在体内的吸收、分布、代谢及排泄与小分子药物相比均存在较大差异。单抗具有的靶点介导的药物处置、非线性药动-代谢、时间依赖性、较长的半衰期等独特的药代动力学特征，使得其在药物研发过程中存在了一系列的挑战。合理的应用模型和仿真技术可帮助研究者充分发掘数据信息、预测临床试验结果、指导临床试验设计以及优化给药方案等，其中靶点介导的药物处置模型在单抗药物研发中的应用目前已有一些探索。本文将通过对单抗药物药动学特征的介绍，探讨靶点介导的药物处置模型在单抗药物研发中应用的可行性和必要性，以期帮助研究者科学、高效地进行单抗类药物的研发。

关键词: 单克隆抗体, 药代动力学, 靶点介导的药物处置

Abstract:

In recent years, monoclonal antibodies have become the area of interest in industry. Unlike small molecules, monoclonal antibodies exhibit unique structural and physiological properties, alongside with differences in absorption, distribution, metabolism and excretion. These unique properties of monoclonal antibodies［e.g. target-mediated drug disposition (TMDD), nonlinear pharmacokinetics, time-dependence and long half-life］ pose several challenges in drug development. Appropriate application of modeling and simulation techniques can help researchers with data mining, predicting clinical trial outcomes, guiding clinical trial designs and optimizing dosing schemes. Among these, the application of the TMDD model in the monoclonal antibody development is growing. In this review, a brief introduction on the pharmacokinetic properties of monoclonal antibodies is provided, followed by a discussion on the feasibility and necessity of applying the TMDD model to monoclonal antibody drug development. The aim of current work is to provide a reference for researchers to scientifically and efficiently conduct studies on the monoclonal antibodies.

Key words: monoclonal antibodies, pharmacokinetics, target-mediated drug disposition

中图分类号:

R969

季双敏，朱校. 靶点介导的药物处置模型在单克隆抗体药物研发中应用的探讨[J]. 中国临床药理学与治疗学, doi: 10.12092/j.issn.1009-2501.2018.03.001.

JI Shuangmin, ZHU Xiao. Application of target-mediated drug disposition (TMDD) models in the development of monoclonal antibody[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, doi: 10.12092/j.issn.1009-2501.2018.03.001.

参考文献

［1］药物临床试验登记与信息公示平台［EB/OL］.http://www.chinadrugtrials.org.cn/
［2］Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine［J］. Nat Rev Immunol, 2004, 4(2): 153-156.
［3］Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, umanized and human recombinant monoclonal antibodies for therapeutic use［J］. Curr Pharm Des, 2008, 14(27): 2883-2891.
［4］Wang Y, Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006［J］. J Clin Pharmacol, 2008, 48(2): 146-156.
［5］国家食品药品监督管理总局药品审评中心统计与临床药理学部.FDA的“创新行动计划”［EB/OL］.http://www.cde.org.cn/dzkw.do?method=largePage&id=313974.
［6］Levy G.Pharmacologic target-mediated drug disposition［J］.Clin Pharmacol Ther,1994,56(3):248-252.
［7］Ryman JT,Meibohm B. Pharmacokinetics of Monoclonal Antibodies［J］. Pharmacometrics Syst Pharmacol, 2017,6(9): 576-588.
［8］Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies［J］.Bio Drugs, 2010， 24(1): 23-39.
［9］Meibohm B. Pharmacokinetics and pharmacodynamics of peptide and protein therapeutics［M］//Crommelin DJA,Sindelar RD,Meibohm B.Pharmaceutical Biotechnology: Fundamentals and Applications.4th Edition.NewYork:Springer,2013:101-132
［10］Huang ML, Peer AV, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects［J］. Clin Pharmacol Ther, 1993，54(3): 257-268.
［11］Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age［J］. Nat Rev Immunol, 2007,7(9): 715-725.
［12］Kontermann RE. Strategies for extended serum half-life of protein therapeutics［J］. Curr Opin Biotechnol, 2011， 22(6): 868-876.
［13］Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats［J］. Drug Metab Dispos, 2013，41(1): 248-255.
［14］FDA 关于IDELVION的审评报告［EB/OL］.https://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm489212.htm.
［15］Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5): 429-451.
［16］Sethu S, Govindappa K, Alhaidari M, et al. Immunogenicity to biologics: mechanisms, prediction and reduction［J］. Arch Immunol Ther Exp (Warsz), 2012, 60(5): 331-344.
［17］Wang Y, Booth B, Rahman A, et al. Toward greater insights on pharmacokinetics and exposure‐response relationships for therapeutic biologics in oncology drug development［J］. Clin Pharmacol Ther, 2017,101(5): 582-584.
［18］Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies［J］. J Pharmacokinet Pharmacodyn, 2013，40(5): 597-607.
［19］Tiwari A, Abraham AK, Harrold JM, et al. Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling［J］. AAPS J, 2017,19(2): 510-519.
［20］Lindauer A, Valiathan CR, Mehta K, et al. Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab［J］.CPT Pharmacometrics Syst Pharmacol，2017，6(1): 11-20.
［21］Dua P, Hawkins E, Van Der Graaf PH. A tutorial on target-mediated drug disposition (TMDD) models［J］. CPT Pharmacometrics Syst Pharmacol, 2015，4(6): 324-337.
［22］Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics［J］. Expert Opin Drug Metab Toxicol, 2009，5(7): 803-812.
［23］Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］. J Pharmacokinet Pharmacodyn, 2001，28(6): 507-532.
［24］Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］. Pharm Res, 2005，22(10): 1589-1596.
［25］Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters［J］. J Pharmacokinet Pharmacodyn, 2008， 35(5): 573-591.
［26］Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours［J］. Clin Pharmacokinet， 2012， 51(4): 247-260.
［27］Luu KT, Bergqvist S, Chen E, et al. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition［J］. J Pharmacol Exp Ther, 2012, 341(3): 702-708.
［28］Kakkar T, Sung C, Gibiansky L, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor［J］. Pharm Res, 2011, 28(10): 2530-2542.
［29］Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models ［J］. J Pharmacokinet Pharmacodyn, 2010,37(1): 25-47.
［30］EMA.Immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use［S］. 2012.
［31］EMA. Guideline on similar biological medicinal products containing monoclonal antibodies- non-clinical and clinical issues［S］. 2012.
［32］高柳村，陈晓媛.关于“贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑”征求意见通知［EB/OL］.http://www.cde.org.cn/news.do?method=viewInfoCommon&id=313925.

[1]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[2]	李梦雪, 何杰, 余霞霞, 胡琳璘, 邵华. 利妥昔单抗群体药代动力学研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 468-474.
[3]	周佳婷, 张玄, 谢子兰, 李智. 肠道菌群与左旋甲状腺素：相互影响与临床意义[J]. 中国临床药理学与治疗学, 2023, 28(11): 1307-1314.
[4]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.
[5]	徐涛, 朱素燕, 邱相君, 徐萍. 肾功能不全患者人群中替考拉宁群体药代动力学模型的建立与验证[J]. 中国临床药理学与治疗学, 2022, 27(9): 977-983.
[6]	马申, 刘玉硕, 唐辉, 陈文斌, 高聆. 改善非酒精性脂肪性肝病药物的药代动力学及其临床意义[J]. 中国临床药理学与治疗学, 2022, 27(8): 908-918.
[7]	戴静怡, 王晶晶, 张菁, 郁继诚, 李南洋, 黄志伟. 吸入性甲氧氟烷的临床应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 808-813.
[8]	潘淑, 吴义金, 张洒洒, 王启海, 罗婷婷, 殷勤. 基于OAT3介导的MTX治疗佐剂诱导性关节炎大鼠的药动学研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 516-525.
[9]	吴娟, 王志强, 周仁鹏, 杨晶晶, 秦慧玲, 张茜, 鲁超, 胡伟. 甲苯磺酸索拉非尼片在中国健康受试者的生物等效性研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 281-286.
[10]	史革鑫, 崇锐, 贺坤, 吴海棠, 周宇, 顿中军, 温清, 张继国, 张荣. 吗替麦考酚酯胶囊在中国健康男性受试者空腹及餐后状态下的完全重复交叉设计的生物等效性研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1255-1263.
[11]	郭璐, 钟振东, 韩奕岑, 石毅, 杨勇, 边原, 刘晓姝, 张静, 郎琴, 钟甜. 不同给药方式在大鼠内对利巴韦林的药代动力学和组织分布的影响[J]. 中国临床药理学与治疗学, 2022, 27(1): 25-32.
[12]	林良沫, 符祥俊, 钟莉莉, 王和芳, 吴琼诗, 肖坚. 中性粒细胞缺乏患者万古霉素群体药代动力学模型的建立[J]. 中国临床药理学与治疗学, 2021, 26(9): 1014-1022.
[13]	付淑军, 黄芳华, 顾景凯, 吴伟, 孙涛, 王庆利. 纳米药物非临床药代动力学的研究策略及关注要点[J]. 中国临床药理学与治疗学, 2021, 26(8): 842-850.
[14]	徐慧, 杨新宇, 赵哲辉, 王琰. 多糖药物体内代谢及PK/PD关键技术研究的进展与思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 851-862.
[15]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.